The Democratic Republic of the Congo has now reported 4,665 confirmed Ebola cases and 2,184 deaths as of 12 August 2026, according to the World Health Organization. WHO says it is the largest Ebola outbreak ever recorded in the country and is “expanding faster than any previous Ebola outbreak.” The virus driving it is Bundibugyo, and as WHO states plainly in its 14 August Disease Outbreak News, “no approved vaccines or specific treatments currently exist” for it.
Key takeaways
- Congo has logged 4,665 confirmed cases and 2,184 deaths, roughly 47 deaths for every 100 confirmed cases.
- This is Bundibugyo virus, not the Zaire species that Ervebo, the only licensed Ebola vaccine, was built against.
- The European Centre for Disease Prevention and Control (ECDC) rates the chance of infection for people living in the EU and EEA as “very low,” and WHO rates global risk as low.
What happened
The outbreak started in one health zone, Mongbwalu in Ituri province, and now covers 54 of 151 health zones across six provinces, per WHO. Ituri carries most of it: 3,979 confirmed cases and 1,726 deaths, which is 85% of the cases and 79% of the deaths nationwide.
That works out to a case fatality ratio of 46.8%. WHO’s 14 August report noted that 1,060 of those cases and 597 of those deaths were added in the two weeks since its previous report. The week of 3 to 9 August set records with 579 cases and 304 deaths.
WHO counted at least 155 confirmed cases among health workers as of 9 August, including 45 deaths, and has recorded 12 attacks on health care since the emergency was declared on 17 May 2026. Three people have been treated in Europe: two cases treated in Germany, and one imported case detected in France on 24 June 2026.
Dr. Kumar’s take
“We have an Ebola vaccine” is a dangerously incomplete sentence, and this outbreak is the proof.
Ervebo is described by WHO as “the only licensed Ebola vaccine (previously known as ebolavirus Zaire).” Bundibugyo is a different species in the same family. That is why WHO’s Technical Advisory Group on 7 August recommended Ervebo be “prioritized for inclusion in a randomized clinical trial” rather than simply shipped and used, and why WHO’s PARTNERS treatment trial, which started enrolling on 2 July and has taken in just over 100 confirmed cases across three facilities in Ituri, exists at all. Those are research questions, not deployed tools, and a trial that has enrolled 100 people is not a shield for six provinces.
A 47% fatality rate at this scale is a different object than the country’s own 2018 to 2020 outbreak, which recorded 3,317 cases. This one is larger, it is killing close to half of confirmed cases while still accelerating, and it is doing it in a conflict zone. A high fatality rate is not only a property of the virus. It reflects how late people reach care.
The realistic American risk is not a traveler landing in Atlanta. Three infected people were already moved to high-containment care in Europe with no onward spread, which is what a working system looks like. The risk is surveillance collapse. This outbreak was confined to a single health zone, Mongbwalu, before it reached 54 health zones in six provinces. Health workers in Bunia have gone on strike over unpaid wages. Crowds have attacked response teams. Every week of missed detection in eastern Congo is a week the rest of the world is flying blind, the same failure mode behind every outbreak that got away from us, including the long tail of polio eradication.
What it means for you
For anyone living in the United States or Europe, this does not change daily behavior. ECDC says the likelihood of infection in the EU and EEA is “very low,” and WHO puts risk for the rest of the world at low.
If you are traveling to or from eastern Congo or western Uganda, the practical point is the incubation window. WHO puts it at two to 21 days, and people are not contagious until symptoms start. A fever after travel to that region deserves a phone call to a clinician before walking into a waiting room, so the visit can be arranged safely.
WHO says control here rests on rapid case identification, isolation and care, contact tracing and safe burials, because the pharmacy shelf is empty for this species. Funding surveillance in a country you will never visit is what keeps that shelf from being the only defense the rest of us have too.